Array BioPharma
Array BioPharma is a U.S.-based, clinical stage, pharmaceutical company that focuses on oncology medication. The company is a subsidiary of Pfizer.History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.
In November 2000, the company became a public company via an initial public offering.
In July 2013, the company partnered with Loxo Oncology to develop cancer drugs.
In November 2015, the company signed a partnership with Laboratoires Pierre Fabre.
In 2016, the company collaborated with Laboratoires Pierre Fabre for a phase three trial for a treatment of BRAF-mutant metastatic colorectal cancer.
In May 2017, the company partnered with Ono Pharmaceutical to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.
In 2017, the company spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.
In March 2018, Array sued AstraZeneca for breach of contract, saying that AstraZeneca owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AstraZeneca in a deal for selumetinib, which Array said it had licensed to AstraZeneca in 2003.
In June 2018, the combination of BRAFTOVI® and MEKTOVI® was approved by the Food and Drug Administration for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
On September 20, 2018, the European Commission approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test.
In July 2019, Pfizer acquired the company for approximately $11 billion.
